Search for


TEXT SIZE

search for



CrossRef (0)
醫낆뼇몴吏옄寃궗 봽濡쒓렇옩 떊鍮숇룄議곗궗 寃곌낵蹂닿퀬(2017)
Annual Report on the External Quality Assessment Scheme for Tumor Markers in Korea (2017)
J Lab Med Qual Assur 2018;40:70-76
Published online June 30, 2018
© 2018 Korean Association of External Quality Assessment Service.

넚긽썕
Sang Hoon Song

꽌슱븰援 쓽怨쇰븰 꽌슱븰援먮퀝썝 吏꾨떒寃궗쓽븰怨

Department of Laboratory Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea
Correspondence to: Sang Hoon Song Department of Laboratory Medicine, Seoul National University Hospital, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul 03080, Korea Tel: +82-2-2072-3326 Fax: +82-2-747-0359 E-mail: cloak21@snu.ac.kr
援먯떊옄: 넚긽썕 슦)03080 꽌슱떆 醫낅줈援 븰濡 101, 꽌슱븰援 쓽怨쇰븰 꽌슱븰援먮퀝썝 吏꾨떒寃궗쓽븰怨 Tel: 02)2072-3326, Fax: 02)747-0359, E-mail: cloak21@snu.ac.kr
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
 Abstract

2017뀈룄 븳엫긽寃궗젙룄愿由ы삊쉶 醫낆뼇몴吏옄 봽濡쒓렇옩뿉꽌뒗 醫낆뼇몴吏옄 I怨 醫낆뼇몴吏옄 II濡 굹늻뼱 alpha-fetoprotein (AFP), carcinoembryonic antigen, prostate specific antigen, protein induced by vitamin K absence-II, cancer antigen (CA) 125, CA 19-9, CA 15-3, CA 72-4, beta-2-microglobulin 벑 珥 9醫낆쓽 寃궗뿉 븯뿬 떊鍮숇룄議곗궗瑜 떆뻾븯떎. 珥 2쉶 떆뻾븯쑝硫, 1쉶李 醫낆뼇몴吏옄 I쓣 젣쇅븯怨, 媛 쉶李⑥뿉 3媛쒖쓽 臾쇱쭏쓣 諛쒖넚 븯떎. 醫낆뼇몴吏옄 I 珥 648湲곌, 醫낆뼇몴吏옄 II뒗 珥 380湲곌씠 李몄뿬븯쑝硫 쉶떊쑉 92.9%-97.0%떎. 蹂씠怨꾩닔뒗 寃궗醫낅쪟 寃泥댁뿉 뵲씪 떎瑜닿쾶 굹궗뒗뜲 룊洹 蹂씠怨꾩닔뒗 3.7%-16.8%떎. 젣議곗궗媛 1媛쒖씤 CA 72-4쓽 蹂씠怨꾩닔媛 媛옣 궙븯怨 留ㅼ슦 넂 냽룄媛 룷븿맂 AFP쓽 蹂씠怨꾩닔媛 媛옣 넂븯떎.

In 2017, the tumor marker program of the Korean Association of External Quality Assessment Service was performed for tumor markers I and II. Tumor marker I comprised alpha-fetoprotein (AFP), carcinoembryonic antigen, protein induced by vitamin K absence-II, and prostate specific antigen (PSA), and tumor marker II comprised cancer antigen (CA) 125, CA 19-9, CA 15-3, CA 72-4, and beta-2-microglobulin. Two challenges were conducted with three pooled serum or control materials, except for the first tumor marker I challenge. In total, 648 institutions participated in tumor marker I and 380 in tumor marker II programs. The response rates were 92.9%97.0%. The coefficients of variation (CVs) were different depending on tests and samples, and average CVs were 3.7%16.8%. The average CV of CA 72-4 tests, whose number of participants was the smallest, was the lowest. The average CV of AFP tests, which included a sample with very high levels, was the highest.

Keywords : Proficiency testing, Tumor marker, Korean Association of External Quality Assessment Service
꽌 濡

2017뀈 李⑥꽭 떊鍮숇룄議곗궗궗뾽쓽 醫낆뼇몴吏옄寃궗 봽濡쒓렇옩 醫낆뼇몴吏옄 I怨 醫낆뼇몴吏옄 II濡 援ъ꽦븯뿬 슫쁺븯떎. 珥 9醫낆쓽 寃궗빆紐⑹뿉 븯뿬 떆뻾븯쑝硫, 醫낆뼇몴吏옄 I뿉뒗 alpha-fetoprotein (AFP), carcinoembryonic antigen (CEA), prostate specific antigen (PSA), protein induced by vitamin K absence or antagonist-II (PIVKA-II)寃궗媛 룷븿릺뼱 엳뿀쑝硫, 醫낆뼇몴吏옄 II뿉뒗 cancer antigen (CA) 125, CA 19-9, CA 15-3, CA 72-4, beta2-microglobulin (B2M)씠 룷븿릺뼱 엳뿀떎. 씠뿉 2017뀈 醫낆뼇몴吏옄 떊鍮숇룄議곗궗궗뾽쓽 寃곌낵瑜 슂빟븯怨 諛쒖쟾諛⑺뼢쓣 紐⑥깋븯怨좎옄 븳떎.

옱猷 諛 諛⑸쾿

醫낆뼇몴吏옄寃궗 봽濡쒓렇옩뿉꽌뒗 긽諛섍린 븯諛섍린濡 굹늻뼱 珥 2쉶 쇅遺젙룄愿由щЪ吏덉쓣 諛쒖넚븯쑝硫, 媛 쉶李 떦 2-3媛쒖쓽 쇅遺젙룄愿由щЪ吏덉쓣 룊媛븯룄濡 븯떎.

醫낆뼇몴吏옄 I쓣 쐞븳 쇅遺젙룄愿由щЪ吏덉 吏곸젒 議곗젣븯떎. 삁븸썝쑝濡쒕꽣 援ъ엯븳 fresh-frozen plasma瑜 竊70째C 씠븯뿉 蹂닿븯떎 議곗젣 吏곸쟾 빐룞븯떎. 빐룞븳 삁옣뿉 怨좊냽룄쓽 옍뿬 寃泥대 샎빀븯뿬 1쉶李⑤뒗 2媛吏, 2쉶李⑤뒗 3媛吏 냽룄쓽 쇅遺젙룄愿由щЪ吏덉쓣 議곗젣븯떎. 옍뿬 寃泥 샎빀 썑 4째C 깋옣떎뿉꽌 援먮컲湲곕 씠슜븯뿬 16떆媛 씠긽 샎빀븯떎. 샎빀 삁옣 3,000 rpm뿉꽌 10遺꾧컙 썝떖遺꾨━븳 썑 옍뿬 移⑥쟾臾쇱쓣 젣嫄고븯湲 쐞빐 0.2 關m 븘꽣濡 옍뿬 移⑥쟾臾쇱쓣 젣嫄고븯떎. 옍뿬 寃泥대뒗 AFP, CEA, PSA, PIVKA-II寃궗媛 쓽猶곕릺뼱 寃궗瑜 떎떆븳 썑쓽 옍뿬 寃泥 以 怨좊냽룄쓽 寃泥대 닔吏묓븯뿬 4째C뿉꽌 깋옣 蹂닿븯떎. 議곗젣븳 쇅遺젙룄愿由щЪ吏덉 냽룄蹂꾨줈 媛곴컖 1 mL뵫 遺꾩<븯뿬 깋룞蹂닿 썑 湲곌뿉 諛쒖넚븯떎.

醫낆뼇몴吏옄 II瑜 쐞븳 쇅遺젙룄愿由щЪ吏덉 Lyphochek Tumor Marker Plus Control (Bio-Rad, Hercules, CA, USA) 臾쇱쭏쓣 씠슜븯떎. 媛 쉶李⑤쭏떎 궙 냽룄, 以묎컙 냽룄, 넂 냽룄쓽 臾쇱쭏濡 援ъ꽦븯뿬 湲곌뿉 諛쒖넚븯떎.

쇅遺젙룄愿由щЪ吏덉 怨꾩빟 깮諛곕 씠슜븯뿬 諛쒖넚븯뒗뜲, 醫낆뼇몴吏옄 I 1쉶李⑤뒗 4썡 24씪뿉, 2쉶李⑤뒗 10썡 16씪뿉, 醫낆뼇몴吏옄 II뒗 1쉶李⑤뒗 3썡 20씪뿉, 2쉶李⑤뒗 9썡 18씪뿉 諛쒖넚븯떎, 寃궗寃곌낵뒗 李⑥꽭 떊鍮숇룄議곗궗궗뾽 솃럹씠吏뿉 엯젰븯룄濡 븯怨, 엯젰湲곌컙 醫낅즺 썑 뜲씠꽣 삤瑜섎 寃利앺븳 썑 넻怨꾨텇꽍쓣 떆뻾븯떎.

넻怨꾨텇꽍 쟾泥 湲곌, 젣議고쉶궗蹂, 痢≪젙湲곌린蹂꾨줈 떆뻾븯떎. 寃궗빆紐 諛 쉶李⑤퀎濡 룊洹(mean), 몴以렪李(standard deviation), 蹂씠怨꾩닔(coefficient of variation), 以묒븰媛(median), 理쒖냼媛(min), 理쒕媛(max)쓣 援ы븯떎. Standard deviation index (SDI)뒗 젣議고쉶궗 옣鍮꾨퀎濡 궛異쒗븯떎. 룊洹, 몴以렪李, 蹂씠怨꾩닔뒗 李몄뿬湲곌쓽 75 pertentile 媛(Q3)怨 25 percentile 媛(Q1)쓽 李(Q3-Q1; interquartile range, IQR)쓽 1.5諛곕 珥덇낵븯뿬 Q1蹂대떎 궙嫄곕굹 Q3蹂대떎 넂 寃곌낵媛(Q1-1.5횞IQR 삉뒗 Q3+1.5횞IQR) 씠긽移(outlier)濡 젣媛븳 썑 遺꾩꽍븯떎. 李몄뿬湲곌쓽 닔媛 10媛 씠긽씤 寃쎌슦뿉뒗 SDI瑜 궛異쒗븯쑝굹, 10媛 誘몃쭔씤 寃쎌슦뿉뒗 SDI瑜 궛異쒗븯吏 븡怨 以묒븰媛, 理쒖냼媛, 理쒕媛믩쭔쓣 궛異쒗븯떎. 李몄뿬湲곌쓽 닔媛 2媛 씠븯씤 寃쎌슦뿉뒗 SDI, 以묒븰媛믪쓣 궛異쒗븯吏 븡怨 理쒖냼媛믨낵 理쒕媛믩쭔쓣 궛異쒗븯떎[1,2].

寃곌낵 諛 怨좎같

1. 떊鍮숇룄議곗궗궗뾽 李몄뿬湲곌

2017뀈 醫낆뼇몴吏옄寃궗 봽濡쒓렇옩 醫낆뼇몴吏옄 I 668湲곌, 醫낆뼇몴吏옄 II뒗 397湲곌씠 떊泥븯뿬 寃泥대 諛쒖넚븯떎. 醫낆뼇몴吏옄 I 1쉶李⑥뿉 627湲곌(93.9%), 2쉶李 648湲곌(97.0%)뿉꽌 쉶떊븯떎. 醫낆뼇몴吏옄 II뒗 1쉶李 369湲곌(92.9%), 2쉶李 380湲곌(95.7%)뿉꽌 쉶떊븯떎.

2. 醫낆뼇몴吏옄寃궗쓽 젣議곗궗 쁽솴

醫낆뼇몴吏옄寃궗쓽 寃곌낵瑜 쉶떊븳 湲곌 紐⑤몢 硫댁뿭痢≪젙옣鍮꾨 궗슜븯怨 엳뿀쑝硫 젣議곗궗蹂꾨줈 遺꾨쪟븷 븣 Roche (Mannheim, Germany)媛 媛옣 留롮븯怨, Abbott (Abbot Park, IL, USA), Siemens (Tarrytown, NY, USA), Beckman Coulter (Brea, CA, USA), bioMerieux (Marcy L섷toile, France), Fujirebio (Tokyo, Japan), Ortho Clinical Diagnostics (Raritan, NJ, USA), Tosoh (Tokyo, Japan), DiaSorin (Dietzenbach, Germany), Wako (Osaka, Japan) 벑쓽 젣議곗궗 옣鍮꾨룄 2湲곌 씠긽뿉꽌 궗슜븯怨 엳뿀떎. 珥 9媛쒖쓽 醫낆뼇몴吏옄寃궗뿉꽌 PIVKA-II B2M쓣 젣쇅븯怨 7媛 寃궗뿉꽌 Roche 옣鍮꾨 궗슜븯뒗 湲곌씠 媛옣 留롮븯떎. PIVKA-II뒗 Wako 삉뒗 Abbott, B2M Biomerieux 옣鍮꾨 궗슜븯뒗 湲곌씠 媛옣 留롮븯떎. Table 1뿉 李몄뿬湲곌쓽 醫낆뼇몴吏옄 寃궗빆紐⑸퀎 젣議곗궗 쁽솴쓣 젙由ы븯떎.

Table 1 . Distribution of manufacturers of tumor marker tests in 2017 proficiency testing.

꺿꺿긎anu짯facturersAFPCEAPSAPIVKA-IICA 125CA 19-9CA 15-3CA 72-4B2M









T1T2T1T2T1T2T1T2T1T2T1T2T1T2T1T2T1T2
Roche278 (44.6)293 (45.4)233 (44.4)241 (45.3)233 (45.5)244 (46.2)154 (44.3)163 (45.5)170 (46.3)179 (47.4)56 (56.6)61 (59.2)14 (100.0)14 (100.0)2 (8.0)2 (8.3)
Abbott162 (26)165 (25.5)143 (27.2)142 (26.7)137 (26.8)136 (25.8)18 (35.3)22 (41.5)107 (30.7)110 (30.7)101 (27.5)105 (27.8)16 (16.2)16 (15.5)
Siemens93 (14.9)94 (14.6)82 (15.6)86 (16.2)77 (15.0)82 (15.5)52 (14.9)54 (15.1)57 (15.5)59 (15.6)12 (12.1)13 (12.6)8 (32.0)6 (25.0)
Beckman49 (7.9)52 (8.0)41 (7.8)42 (7.9)37 (7.2)37 (7.0)25 (7.2)23 (6.4)28 (7.6)27 (7.1)12 (12.1)11 (10.7)
Biomerieux24 (3.8)24 (3.7)11 (2.1)11 (2.1)13 (2.5)15 (2.8)4 (1.1)4 (1.1)5 (1.4)4 (1.1)3 (3.0)2 (1.9)10 (40.0)10 (41.7)
Fujirebio8 (1.3)6 (0.9)7 (1.3)5 (0.9)6 (1.2)5 (0.9)11 (21.6)10 (18.9)3 (0.9)2 (0.6)3 (0.8)2 (0.5)
Ortho Clinical Diagnostics5 (0.8)5 (0.8)4 (0.8)3 (0.6)4 (0.8)3 (0.6)3 (0.9)2 (0.6)3 (0.8)2 (0.5)
Tosoh3 (0.5)4 (0.6)2 (0.4)2 (0.4)2 (0.4)2 (0.4)
Diasorin5 (20.0)6 (25.0)
Wako22 (43.1)21 (39.6)
Others2 (0.3)3 (0.5)2 (0.4)3 (0.6)4 (0.8)
Sum624 (100.0)646 (100.0)525 (100.0)532 (100.0)512 (100.0)528 (100.0)51 (100.0)53 (100.0)348 (100.0)358 (100.0)367 (100.0)378 (100.0)99 (100.0)103 (100.0)14 (100.0)14 (100.0)25 (100.0)24 (100.0)

Values are presented as number (%).

Abbreviations: AFP, alpha-fetoprotein; CEA, carcinoembryonic antigen; PSA, prostate specific antigen; PIVKA-II, protein induced by vitamin K absence-II; CA, cancer antigen; B2M, beta-2-microglobulin.


3. 醫낆뼇몴吏옄寃궗 떊鍮숇룄議곗궗궗뾽 寃곌낵

珥 9媛쒖쓽 醫낆뼇몴吏옄寃궗瑜 긽쑝濡 2쉶뿉 嫄몄퀜 珥 5媛쒖쓽 寃泥, 利 45媛 寃곌낵媛믪쓽 遺꾪룷瑜 遺꾩꽍븳 寃곌낵 醫낆뼇몴吏옄寃궗 쟾泥댁쓽 룊洹 蹂씠怨꾩닔뒗 10.8%떎. 씠 以 媛옣 궙 蹂씠怨꾩닔瑜 굹궦 寃쎌슦뒗 CT2-17-03 寃泥댁쓽 CA 72-4怨, 媛옣 궙 蹂씠怨꾩닔瑜 굹궦 寃쎌슦뒗 CT1-17-05 寃泥댁쓽 AFP떎. CA 72-4쓽 寃쎌슦 李몄뿬湲곌씠 궗슜븯怨 엳뒗 젣議곗궗媛 1媛쒖씠誘濡 蹂씠怨꾩닔媛 媛옣 궙 媛믪쓣 蹂댁씤 寃껋쑝濡 異붿젙릺硫, CT1-17-05 寃泥댁쓽 AFP뒗 룊洹 냽룄媛 1,900.96 ng/mL濡 留ㅼ슦 넂 媛믪씠뼱꽌 젣議곗궗, 옣鍮꾨퀎 蹂댁젙臾쇱쭏쓽 踰붿쐞, 씗꽍 뿬遺, 씗꽍諛⑸쾿 벑뿉 뵲씪 李⑥씠媛 겕寃 궃 寃껋쑝濡 異붿젙맂떎. 蹂씠怨꾩닔媛 겕誘濡 씠긽移섏쓽 鍮꾩쑉씠 넂쓣 寃껋쑝濡 삁긽븷 닔룄 엳쑝굹 몴以렪李④ 겕湲 븣臾몄뿉 씠긽移섎줈 젣嫄곕맂 옄猷뚯쓽 鍮꾩쑉 떎瑜 寃궗 삉뒗 寃泥댁뿉 鍮꾪빐 궙븯떎. 뼢썑뿉 엫긽쟻쑝濡 굹궇 닔 엳뒗 留ㅼ슦 궙 媛 삉뒗 넂 媛믪쓣 씠슜븳 쇅遺젙룄愿由щ 솗옣븳떎硫 씠윭븳 쁽긽쓽 쁽솴쓣 뙆븙븯湲 슜씠븷 寃껋쑝濡 깮媛곷맂떎. 씠긽移섎줈 젣嫄곕맂 寃곌낵쓽 鍮꾩쑉 룊洹 5% 궡쇅뒗뜲 뼱뼡 湲곗쓣 쟻슜븯뒓깘뿉 뵲씪꽌 留ㅼ슦 겙 李⑥씠媛 굹뒗 寃궗 삉뒗 寃泥닿 엳뿀떎. 삁瑜 뱾硫, CT1-17-01 寃泥댁뿉꽌 PIVKA-II쓽 寃쎌슦 씠긽移섏쓽 鍮꾩쑉씠 李몄뿬湲곌 쟾泥대 peer group쑝濡 삎꽦븷 븣뒗 13.7%, 젣議곗궗 삉뒗 옣鍮꾨 湲곗쑝濡 peer group쓣 븷 븣뒗 2.0%濡 李몄뿬湲곌 쟾泥대 湲곗쑝濡 븷 븣 6諛 씠긽 씠긽移섏쓽 鍮꾩쑉씠 넂븯떎. CT1-17-05 寃泥댁뿉꽌 AFP쓽 寃쎌슦 씠긽移섏쓽 鍮꾩쑉씠 李몄뿬湲곌 쟾泥대 peer group쑝濡 삎꽦븷 븣뒗 0%, 젣議곗궗瑜 湲곗쑝濡 peer group쓣 븷 븣뒗 3.6%, 옣鍮꾨 湲곗쑝濡 peer group쓣 븷 븣뒗 5.0%濡 쟾泥대낫떎뒗 젣議곗궗, 옣鍮 媛 李⑥씠媛 겙 寃쏀뼢씠 엳뿀떎. 씠긽移섎줈 젣嫄곕맂 寃곌낵쓽 鍮꾩쑉 쟾泥(4.5%) 삉뒗 옣鍮(4.5%) 湲곗씪 븣蹂대떎뒗 젣議곗궗(5.4%)瑜 湲곗쑝濡 븷 븣媛 빟媛 넂 寃쏀뼢씠 엳뿀떎. 洹몃윭굹, 쟾泥대 湲곗쑝濡 븯뒗 寃쎌슦 씠긽移섎줈 젣嫄곕릺뒗 鍮꾩쑉쓽 蹂룞씠 媛옣 떖븯뿬꽌 듅젙븳 젣議곗궗쓽 寃곌낵媛 떎瑜 젣議곗궗뱾怨 겕寃 李⑥씠媛 굹뒗 寃쎌슦 쟾泥대 湲곗쑝濡 븯뒗 궛異쒖뿉꽌 젣쇅맆 媛뒫꽦씠 넂떎뒗 寃껋쓣 異붿젙븷 닔 엳떎. 듅엳 李몄뿬湲곌쓽 닔媛 쟻 젣議곗궗씪닔濡 쟾泥대 湲곗쑝濡 븷 븣 씠긽移섎줈 젣嫄곕맆 媛뒫꽦씠 넂떎怨 븷 닔 엳떎. 씠윭븳 쁽긽 븵쑝濡 씪移섑솕 삉뒗 몴以솕 떆 李멸퀬븷 닔 엳쓣 寃껋쑝濡 깮媛곷맂떎. Table 2뿉 寃궗蹂, 寃泥대퀎 援ъ껜쟻씤 옄猷뚮 젙由ы븯떎.

Table 2 . 2017 proficiency testing results for tumor marker tests.

Test nameSample no.No. of participantsMeanAverageCV (%)MedianMinMaxOutliers (%)

AllManu짯facturerInstru짯ment
AFP (ng/mL)CT1-17-016272.440.229.02.40.0189.111.27.25.2
CT1-17-02627215.1619.299.0210.91.9306.31.95.65.5
CT1-17-036489.890.727.39.90.82523.55.46.85.3
CT1-17-04648351.4128.108.0349.010.3880.63.46.36.4
CT1-17-056481,900.96686.1936.12,000.010.23,434.00.03.65.0
CEA (ng/mL)CT1-17-015261.250.2217.81.30.011.53.66.55.0
CT1-17-025263.670.4211.33.70.05.11.76.75.0
CT1-17-035369.631.9219.910.32.414.50.76.24.6
CT1-17-045364.180.276.44.11.07.217.55.64.2
CT1-17-055366.720.517.56.81.011.311.99.23.8
PSA (ng/mL)CT1-17-015130.650.069.80.70.46.02.55.76.1
CT1-17-025133.680.267.13.70.45.09.07.06.5
CT1-17-035300.510.0611.20.50.3467.01.92.73.8
CT1-17-045300.760.079.40.80.5731.03.22.52.1
CT1-17-055304.340.368.34.40.56.75.85.53.8
PIVKA-II (mAU/mL)CT1-17-015116.901.7010.217.011.022.013.72.02.0
CT1-17-0251343.0037.4010.9352.0285.0416.00.03.93.9
CT1-17-035331.702.909.032.026.036.00.00.00.0
CT1-17-0453421.0064.8015.4445.0332.0550.00.00.00.0
CT1-17-05531,543.50213.3013.81,634.01,207.01,891.00.07.55.8
CA 125 (U/mL)CT2-17-0135033.975.1915.333.19.9194.80.95.76.4
CT2-17-02350105.1617.3516.5102.138.4365.00.64.64.1
CT2-17-03350216.5539.6818.3208.60.0402.64.95.75.3
CT2-17-0436034.655.5115.932.712.846.20.35.65.7
CT2-17-0536084.9815.2918.080.530.7207.90.37.86.8
CT2-17-06360237.2646.7919.7221.575.6356.10.07.35.1
CA 19-9 (U/mL)CT2-17-0136927.822.478.927.814.337.45.15.76.4
CT2-17-0236971.7910.0113.974.537.3230.81.95.44.7
CT2-17-03369201.5828.8714.3208.10.0314.52.77.96.4
CT2-17-0438030.153.8712.830.414.842.60.35.65.9
CT2-17-0538070.1711.3816.275.436.7215.90.55.36.7
CT2-17-06380217.9214.876.8216.379.7327.67.18.56.5
CA 15-3 (U/mL)CT2-17-0110123.652.5910.924.310.228.05.05.12.1
CT2-17-0210152.743.787.253.422.772.910.99.16.3
CT2-17-03101101.527.167.1102.138.1117.011.96.14.2
CT2-17-0410523.392.3910.224.18.933.16.78.75.0
CT2-17-0510557.043.456.057.123.383.414.39.75.9
CT2-17-06105112.815.625.0112.940.8304.519.010.711.9
CA 72-4 (U/mL)CT2-17-01144.620.255.44.64.35.20.00.00.0
CT2-17-021411.660.494.211.810.912.30.00.00.0
CT2-17-031440.510.812.040.537.142.27.17.10.0
CT2-17-04145.410.183.45.55.15.70.00.00.0
CT2-17-051414.540.543.714.613.615.60.00.00.0
CT2-17-061449.011.432.948.644.951.47.17.10.0
B2M (mg/L)CT2-17-01271.620.1710.71.71.31.90.04.04.5
CT2-17-02273.810.328.43.92.94.30.00.04.5
CT2-17-03276.060.6210.36.14.07.13.74.04.5
CT2-17-04271.530.2415.81.61.02.00.012.59.1
CT2-17-05273.740.195.23.72.94.918.54.29.1
CT2-17-06275.880.539.06.04.87.63.74.24.5

Abbreviations: CV, coefficients of variation; AFP, alpha-fetoprotein; CEA, carcinoembryonic antigen; PSA, prostate specific antigen; PIVKA-II, protein induced by vitamin K absence-II; CA, cancer antigen; B2M, beta-2-microglobulin.


醫낆뼇몴吏옄寃궗蹂꾨줈뒗 CA 72-4쓽 룊洹 蹂씠怨꾩닔媛 3.7%濡 媛옣 궙븯怨, CA 125쓽 룊洹 蹂씠怨꾩닔媛 16.8%濡 媛옣 넂븯떎. CA 72-4쓽 蹂씠怨꾩닔媛 궙 寃곌낵뒗 삁痢 媛뒫븯쑝굹, CA 125뿉꽌 蹂씠怨꾩닔媛 넂 寃곌낵뒗 삁痢≫븯吏 紐삵븳 寃곌낵떎. 씠윭븳 쁽긽 寃泥댁 냽룄뿉 긽愿뾾씠 쑀궗븯寃 愿李곕릺뿀뒗뜲, 씠뒗 CA 125쓽 젣議곗궗 媛 李⑥씠媛 떎瑜 寃궗뿉 鍮꾪빐꽌 겮쓣 떆궗븳떎怨 븷 닔 엳떎. Table 3뿉 寃궗蹂 蹂씠怨꾩닔쓽 遺꾪룷瑜 젙由ы븯떎.

Table 3 . Coefficients of variation of tumor marker tests in 2017 proficiency testing (%).

꺿꺿긖est nameMean짹 standard deviation
Alpha-fetoprotein13.9짹12.4
Carcinoembryonic antigen12.6짹6.1
Prostate specific antigen9.2짹1.6
Protein induced by vitamin K absence-II11.9짹2.7
CA 12516.8짹1.3
CA 19-913.2짹2.7
CA 15-38.3짹2.1
CA 72-43.7짹1.2
Beta-2-microglobulin10.1짹3.9

Abbreviation: CA, cancer antigen.


醫낆뼇몴吏옄寃궗쓽 젣議곗궗 媛 李⑥씠뒗 寃궗醫낅쪟 寃泥댁뿉 뵲씪 떎瑜 뼇긽쓣 굹깉뒗뜲, 蹂씠怨꾩닔媛 媛옣 겙 寃泥댁씤 CT1-17-05뿉꽌 洹 李⑥씠媛 媛옣 몢뱶윭吏寃 굹궗떎. Fig. 1뿉 醫낆뼇몴吏옄 寃궗蹂 젣議곗궗 以묒븰媛믪쓽 李⑥씠瑜 몴떆븯떎.

Figure 1.

(A밐) Manufacturer-dependent differences in tumor marker tests in 2017 proficiency testing. The median values from manufacturers with the largest participant numbers were fixed as 100% and the ratios to remaining manufacturers were calculated. Abbreviations: AFP, alpha-fetoprotein; CEA, carcinoembryonic antigen; PSA, prostate specific antigen; PIVKA-II, protein induced by vitamin K absence-II; CA, cancer antigen; B2M, beta-2-microglobulin.


2017뀈 醫낆뼇몴吏옄寃궗쓽 떊鍮숇룄議곗궗궗뾽뿉꽌뒗 醫낆뼇몴吏옄 I 젙긽씤 삁옣怨 솚옄 삁泥쓣 씠슜븯뿬 議곗젣븳 臾쇱쭏쓣 諛쒖넚뻽뒗뜲, 醫낆뼇몴吏옄 II 蹂씠怨꾩닔쓽 遺꾪룷媛 쑀궗븯뿬 긽슜솕맂 臾쇱쭏怨 쑀궗븳 꽦뒫쓣 굹깂쓣 솗씤븷 닔 엳뿀떎. 떊鍮숇룄議곗궗臾쇱쭏쓣 吏곸젒 議곗젣븯뒗 寃껋 遺꾩꽍臾쇱쭏쓽 냽룄瑜 떎뼇솕븿쑝濡쒖뜥 떎젣 엫긽쟻쑝濡 쓽誘 엳뒗 뿬윭 냽룄瑜 룊媛븯嫄곕굹 寃異쒗븳怨 삉뒗 痢≪젙踰붿쐞뿉 愿븳 옄猷뚮 異뺤쟻븷 닔 엳뒗 옣젏씠 엳떎. 븞젙꽦, 洹좎쭏꽦쓣 솗蹂댄븷 닔 엳떎硫 醫낆뼇몴吏옄 II濡쒕룄 솗븷 닔 엳쓣 寃껋쑝濡 깮媛곷맂떎.

References
  1. Lee YK. Routine Hematology Program, Korean Association of External Quality Assessment Service. Annual report on the external quality assessment scheme for routine hematology in Korea (2016). J Lab Med Qual Assur 2017;39:53-60.
    CrossRef
  2. Lee YW, Jeon BR, Kim JG, Jun SH, Yun YM, Chun S, et al. Annual report on the external quality assessment scheme for routine clinical chemistry in Korea (2016). J Lab Med Qual Assur 2017;39:61-75.
    CrossRef